Expert Opinion on Pharmacotherapy最新文献_第4页

Management of erythromelalgia: a narrative review and expert opinion. 红斑性肢痛的治疗：叙述回顾和专家意见。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-15 DOI: 10.1080/14656566.2026.2734121

Jumana Aldhalaan, Julio C Sartori-Valinotti, Mark Denis P Davis, Paola Sandroni

{"title":"Management of erythromelalgia: a narrative review and expert opinion.","authors":"Jumana Aldhalaan, Julio C Sartori-Valinotti, Mark Denis P Davis, Paola Sandroni","doi":"10.1080/14656566.2026.2734121","DOIUrl":"10.1080/14656566.2026.2734121","url":null,"abstract":"Introduction: Erythromelalgia (EM) is a rare disorder predominantly affecting distal extremities characterized by episodes of painful burning erythema, often precipitated by heat and exercise. Treatment is challenging due to limited evidence and lack of guidelines.Areas covered: This article provides an overview of the available literature on EM, with special emphasis on management strategies including lifestyle modification, nonpharmacologic, pharmacologic, procedural, and rehabilitative interventions. PubMed was searched using the advanced search function with the terms 'erythromelalgia AND therapies AND management' from database inception through 16 April 2026.Expert opinion: Management of EM is challenging as there is no cure. It requires an individualized step wise approach due to its heterogenous presentation and variable treatment responses. The primary goal of treatment is to control symptoms and maintain quality of life. In this article, we outline our treatment approach for management including an initial evaluation for underlying causes or associations and treating them if present. First-line therapies include lifestyle modifications, trigger avoidance, and trial of various topical therapies. If not fully responding to first line therapy, we consider initiation of systemic therapies and pain rehabilitative programs.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives. Sjögren疾病的免疫抑制和免疫调节疗法：现状和未来展望。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-12 DOI: 10.1080/14656566.2026.2734124

Veli Yazisiz

{"title":"Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.","authors":"Veli Yazisiz","doi":"10.1080/14656566.2026.2734124","DOIUrl":"https://doi.org/10.1080/14656566.2026.2734124","url":null,"abstract":"Introduction: Sjögren's disease (SjD) is a systemic autoimmune disorder primarily affecting exocrine glands alongside heterogeneous organ involvement. Historically managed through symptomatic relief and conventional disease-modifying therapies, recent immunological advances have steadily expanded our understanding of its pathogenesis and therapeutic approaches.Areas covered: A systematic literature review regarding therapeutic agents for SjD treatment was conducted across the PubMed, Web of Science, Embase, and Cochrane Library databases.Expert opinion: Over the past two decades, significant advancements in immunology have profoundly deepened our understanding of SjD pathogenesis. This pathophysiological insight is facilitating a paradigm shift from conventional symptomatic relief toward targeted, phenotype-driven biological interventions. The therapeutic pipeline investigating novel agents - including B-cell depletion therapies, BAFF/APRIL pathway inhibitors, T-cell/B-cell interaction modulators (e.g. CD40-CD40L, CTLA-4), type I interferon blockade, and JAK-STAT inhibitors - is expanding rapidly. CAR-T cell therapy application in refractory SjD patients currently represents an emerging, strictly experimental approach requiring rigorous evaluation of safety and long-term feasibility. Ultimately, identifying the most effective therapeutic agents will likely require discovering and implementing biomarkers tailored to specific biological endotypes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Operational definition, pharmacotherapy, and clinical trial considerations in developmental and epileptic encephalopathies. 发育性和癫痫性脑病的操作定义、当前和新出现的药物治疗以及临床试验考虑。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-10 DOI: 10.1080/14656566.2026.2729299

Debopam Samanta

引用次数: 0

Evaluating deucrictibant for the treatment of hereditary angioedema. 评价去氧剂治疗遗传性血管性水肿的疗效。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-08-26 DOI: 10.1080/14656566.2026.2722317

Van Bui, Shane Stone, Bharosha Bhattarai, Long Hoang Luong, Mai Thi Vu, E Pelinsu Aydin, Timothy Craig

{"title":"Evaluating deucrictibant for the treatment of hereditary angioedema.","authors":"Van Bui, Shane Stone, Bharosha Bhattarai, Long Hoang Luong, Mai Thi Vu, E Pelinsu Aydin, Timothy Craig","doi":"10.1080/14656566.2026.2722317","DOIUrl":"10.1080/14656566.2026.2722317","url":null,"abstract":"Introduction: Hereditary Angioedema (HAE) is a rare disease affecting approximately 1 in 50,000 people. It results in angioedema of the skin, abdominal tract and upper airway that results in disfiguration, abdominal pain and potential for asphyxia. Early therapies for HAE have significant drug burden due to intravenous administration (C1-inhibitor) or adverse events (androgens); however, newer therapies have reduced injection requirements, and some are oral. Over the past 6 years two oral therapies have been developed for HAE to include berotralstat for long term prophylaxis (LTP) and sebetralstat for on-demand therapy (ODT). Presently, deucrictibant, another oral HAE therapy, is under investigation and appears effective for LTP and ODT.Areas covered: This manuscript summarizes the development, pharmacokinetics, pharmacodynamics, and currently available clinical evidence regarding deucrictibant in HAE management.Expert opinion: Deucrictibant is a promising therapeutic agent with a well-defined mechanism of action. Published and ongoing clinical studies demonstrate favorable safety, tolerability, and efficacy profiles for both LTP and ODT, offering a convenient oral alternative that may reduce treatment burden and improve patient quality of life.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1399-1406"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New and novel pharmacotherapies for hemophilia A: an update. 血友病A的新药物治疗：最新进展。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-08-25 DOI: 10.1080/14656566.2026.2722319

Anna Chiara Giuffrida, Daniele Focosi, Marco Bodini, Matteo Zani, Massimo Franchini

{"title":"New and novel pharmacotherapies for hemophilia A: an update.","authors":"Anna Chiara Giuffrida, Daniele Focosi, Marco Bodini, Matteo Zani, Massimo Franchini","doi":"10.1080/14656566.2026.2722319","DOIUrl":"10.1080/14656566.2026.2722319","url":null,"abstract":"Introduction: Hemophilia A (HA) management has progressed significantly, yet standard and extended half-life (EHL) clotting factors present persistent limitations, including intravenous burden and suboptimal trough levels.Areas covered: This narrative review highlights recently approved agents and phase III candidates for HA. In replacement therapy, efanesoctocog alfa maintains normal-to-near-normal factor VIII (FVIII) levels weekly by bypassing endogenous von Willebrand factor dependence. In non-replacement therapies, the focus centers on rebalancing agents-the anti-tissue factor pathway inhibitor (TFPI) monoclonal antibodies concizumab and marstacimab, and the antithrombin-targeting small interfering RNA (siRNA) fitusiran-as well as next-generation FVIII-mimetics like denecimig. With this objective, a structure literature search of the main original manuscripts and reviews published in English in major medical databases, including PubMed, EMBASE, and Cochrane Library from 2016 to now was conducted.Expert opinion: While these innovators promise near-zero bleeding rates and subcutaneous convenience, they introduce unique challenges. Rebalancing therapies present potential thromboembolic risks, complex breakthrough bleed protocols, and standard laboratory assay interference (requiring antithrombin monitoring or specialized assays). Critical goals for contemporary hemophilia management include tailoring therapies through multidisciplinary collaboration, monitoring subclinical joint disease via point-of-care ultrasound, and implementing standardized, real-world protocols for emergency hemostasis.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1467-1484"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors. 糖尿病肾病的新疗法：超越SGLT2抑制剂

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-09-08 DOI: 10.1080/14656566.2026.2723583

Huajing Ni, Simon Piggott, Maria Carolina Festa, Labib Faruque, David Z I Cherney

{"title":"Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors.","authors":"Huajing Ni, Simon Piggott, Maria Carolina Festa, Labib Faruque, David Z I Cherney","doi":"10.1080/14656566.2026.2723583","DOIUrl":"10.1080/14656566.2026.2723583","url":null,"abstract":"Introduction: Diabetic kidney disease (DKD) remains the leading cause of kidney failure and death worldwide despite established therapies targeting the renin-angiotensin system and, more recently, sodium glucose cotransporter-2 inhibitors. Although contemporary guideline-directed therapy has substantially improved kidney and cardiovascular outcomes, significant residual risk of disease progression persists. This unmet need has driven the development of a new generation of therapies targeting complementary metabolic, inflammatory, fibrotic, and hemodynamic pathways implicated in DKD pathogenesis.Areas covered: This review summarizes contemporary guideline-directed therapy for DKD and examines emerging therapeutic strategies targeting complementary pathways implicated in kidney disease progression. These include novel incretin-based therapies, aldosterone synthase inhibitors, endothelin receptor antagonists, soluble guanylate cyclase activators, and therapies directed against inflammatory and fibrotic mediators. We also discuss the growing role of combination therapy, implementation challenges, and future precision medicine approaches aimed at further reducing residual cardiorenal risk.Expert opinion: Advances in the management of DKD support a paradigm shift from sequential escalation to early combination therapy aimed at maximizing cardiorenal protection and will require novel care models. Significant gaps remain in extending cardiorenal protective therapies to understudied high-risk groups, including type 1 diabetes. Further research should also focus on real-world outcomes beyond albuminuria reduction and target kidney disease remission.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1485-1501"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medication-overuse headache in migraine: could GLP-1 receptor agonists treat the addiction-like phenotype? 偏头痛的药物过度使用头痛：GLP-1受体激动剂能治疗成瘾样表型吗？

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-08-10 DOI: 10.1080/14656566.2026.2716375

Lanfranco Pellesi, Simona Guerzoni

引用次数: 0

Pharmacotherapeutic considerations for the treatment of post-traumatic stress disorder during and after pregnancy: an update. 在怀孕期间和之后治疗创伤后应激障碍的药物治疗考虑：更新。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-01 DOI: 10.1080/14656566.2026.2725862

Christina Gonzalez-Torres, Hoda Seens, Verinder Sharma

{"title":"Pharmacotherapeutic considerations for the treatment of post-traumatic stress disorder during and after pregnancy: an update.","authors":"Christina Gonzalez-Torres, Hoda Seens, Verinder Sharma","doi":"10.1080/14656566.2026.2725862","DOIUrl":"10.1080/14656566.2026.2725862","url":null,"abstract":"Introduction: Post-traumatic stress disorder (PTSD) is a debilitating mental disorder that can cause significant distress to patients and their families. It affects women disproportionately, presenting during pregnancy and the postpartum period. It often goes unrecognized and undertreated, with deleterious consequences for the mother and offspring. The first-line treatment for PTSD in pregnancy and during lactation is psychotherapy; however, when it is not feasible or effective, pharmacotherapy is preferred.Areas covered: This is a narrative review discussing the efficacy and safety of different classes of psychoactive medications for PTSD during pregnancy and the postpartum period. Currently, there are no randomized controlled trials assessing the efficacy and safety of psychoactive medications specifically for PTSD during pregnancy and lactation. Therefore, guidelines recommend treatment with sertraline, paroxetine, or venlafaxine.Expert opinion: Identifying pregnant or postpartum patients with high vulnerability for PTSD and promptly diagnosing, treating, and closely monitoring their response is crucial in the delivery of individualized, high-quality care. Few medications are recommended for the management of PTSD during pregnancy and lactation. In the future, research must focus on the development of safe and effective interventions to ensure the delivery of inclusive healthcare for women in all life stages.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148826613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating bezuclastinib for the treatment of advanced gastrointestinal stromal tumours. 评价贝祖司替尼治疗晚期胃肠道间质瘤的疗效。

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-09-14 DOI: 10.1080/14656566.2026.2721561

Antoine Italiano

{"title":"Evaluating bezuclastinib for the treatment of advanced gastrointestinal stromal tumours.","authors":"Antoine Italiano","doi":"10.1080/14656566.2026.2721561","DOIUrl":"10.1080/14656566.2026.2721561","url":null,"abstract":"Introduction: Advanced gastrointestinal stromal tumors (GISTs) are usually driven by KIT or PDGFRA and treated with sequential tyrosine kinase inhibitors. After imatinib, several distinct secondary KIT-resistant clones may coexist within and between lesions, limiting the coverage of any single later-line inhibitor.Areas covered: This Drug Evaluation reviews the chemistry, active-state pharmacology, preclinical activity, pharmacokinetics, clinical efficacy, safety and regulatory status of bezuclastinib, with emphasis on its combination with sunitinib. PubMed, ClinicalTrials.gov, regulatory sources and major congress proceedings were searched through 13 August 2026.Expert opinion: Bezuclastinib is best viewed as a combination-enabling type I KIT inhibitor that complements the type II inhibitor sunitinib. In PEAK, the combination improved median progression-free survival from 9.2 to 16.5 months and objective response rate from 25.8% to 45.6%, at the cost of more grade 3 or higher toxicity and treatment modification. Pending approval, it is likely to become a preferred second-line option for suitable patients with KIT-driven GIST. Mature survival, post-combination sequencing, resistance mechanisms, long-term patient-reported outcomes and real-world tolerability remain important evidence gaps.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1417-1422"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pearls and pitfalls of oral carbapenem/penem agents: the promise of a new era or the risk of amplified resistance? 口服碳青霉烯类药物的优点和缺陷：新时代的希望还是耐药性扩大的风险？

IF 3.4 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2026-09-01 Epub Date: 2026-08-22 DOI: 10.1080/14656566.2026.2720060

Muhammed Cihan Işık, Murat Akova

{"title":"Pearls and pitfalls of oral carbapenem/penem agents: the promise of a new era or the risk of amplified resistance?","authors":"Muhammed Cihan Işık, Murat Akova","doi":"10.1080/14656566.2026.2720060","DOIUrl":"10.1080/14656566.2026.2720060","url":null,"abstract":"Introduction: The rising prevalence of MDR Gram-negative infections, particularly ESBL-producing Enterobacterales, has created a critical oral treatment gap, necessitating prolonged intravenous therapy. Oral carbapenems/penems offer a long-awaited opportunity to bridge this gap.Areas covered: This review examines the chemistry, pharmacokinetics/pharmacodynamics, and phase 3 trial evidence for tebipenem and sulopenem, recently FDA-approved for urinary tract infections (UTI). We analyze the regulatory landscape pearls and pitfalls of these agents, and their management through an outpatient antimicrobial stewardship (AMS) perspective. Literature was searched in PubMed, Scopus, ClinicalTrials.gov, and regulatory databases through June 2026.Expert opinion: Oral carbapenems/penems evoke enthusiasm over closing a long-standing oral treatment gap for MDR Gram-negative infections, alongside apprehension regarding resistance risks. With both agents now approved in the United States, this promise is now a reality, marking the start of a new era in oral therapy. However, global regulatory fragmentation and evidence limited to UTIs remain key barriers to broader clinical use. Crucially, growing use may shift carbapenem selection pressure from hospitals into the community. This risk requires strict resistance surveillance and formulary restriction to confirmed MDR infections lacking oral alternatives. Their clinical trajectory will depend less on intrinsic activity than on the rigor of AMS frameworks governing their use.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1433-1446"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148790043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0